[144] Acadia Pharmaceuticals Inc. SEC Filing
Acadia Pharmaceuticals (ACAD) filing a Form 144 to notify a proposed sale of securities. The notice identifies 22,000 shares of common stock to be sold through Piper Sandler & Co. on or about 08/18/2025, with an aggregate market value of $557,260.00. The filing shows the shares were acquired as compensation from the issuer on 11/17/2023 and payment was recorded on that date. The filing lists total shares outstanding as 168,712,220. Several standard filer and issuer identification fields in the form are blank, and no name is provided for the person on whose account the sale will occur.
Acadia Pharmaceuticals (ACAD) ha presentato un Modulo 144 per notificare una proposta di vendita di titoli. L鈥檃vviso indica la vendita di 22.000 azioni ordinarie tramite Piper Sandler & Co. intorno al 18/08/2025, con un valore di mercato complessivo di $557.260,00. La comunicazione riporta che le azioni sono state acquisite come retribuzione dall鈥檈mittente il 17/11/2023 e che il pagamento 猫 stato registrato in quella data. Il documento indica un totale di azioni in circolazione pari a 168.712.220. Diversi campi standard relativi all鈥檌dentificazione del dichiarante e dell鈥檈mittente nel modulo risultano vuoti e non 猫 fornito il nome della persona per conto della quale avverr脿 la vendita.
Acadia Pharmaceuticals (ACAD) present贸 un Formulario 144 para notificar una propuesta de venta de valores. El aviso identifica 22.000 acciones ordinarias que se vender谩n a trav茅s de Piper Sandler & Co. alrededor del 18/08/2025, con un valor de mercado agregado de $557.260,00. La presentaci贸n indica que las acciones se adquirieron como 谤别迟谤颈产耻肠颈贸苍 por parte del emisor el 17/11/2023 y que el pago se registr贸 en esa fecha. El formulario se帽ala un total de acciones en circulaci贸n de 168.712.220. Varios campos est谩ndar de identificaci贸n del declarante y del emisor en el formulario est谩n en blanco y no se proporciona el nombre de la persona en cuya cuenta se realizar谩 la venta.
Acadia Pharmaceuticals(ACAD)臧赌 歃濌秾 毵り皝 鞓堨爼 靷嫟鞚� 韱奠頃橁赴 鞙勴暣 Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 瓿奠鞐愲姅 22,000欤� 氤错喌欤�臧赌 Piper Sandler & Co.毳� 韱淀暣 2025/08/18瓴� 毵り皝霅� 鞓堨爼鞚措┌, 齑� 鞁滉岸年岸� $557,260.00搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滌棎電� 頃措嫻 欤检嫕鞚� 氤挫垬(氤挫儊)搿� 氚滍枆靷攵�韯� 2023/11/17鞐� 旆摑霅橃棃瓿� 攴� 雮犾鞐� 歆�旮夓澊 旮半霅橃棃雼り碃 鞝來榾 鞛堨姷雼堧嫟. 靹滊鞐愲姅 齑� 氚滍枆欤检嫕靾橁岸� 168,712,220欤茧 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞏戩嫕鞚� 鞐煬 響滌 鞁犼碃鞚� 氚� 氚滍枆鞚� 鞁濍硠 頃鞚� 牍勳柎 鞛堦碃, 毵り皝鞚� 鞚措（鞏挫 瓿勳鞚� 鞁れ牅 氇呾弓鞚� 鞝滉车霅橃 鞎婌晿鞀惦媹雼�.
Acadia Pharmaceuticals (ACAD) a d茅pos茅 un formulaire 144 pour notifier une vente propos茅e de titres. L鈥檃vis indique la vente de 22 000 actions ordinaires par l鈥檌nterm茅diaire de Piper Sandler & Co. autour du 18/08/2025, pour une valeur marchande totale de 557 260,00 $. Le d茅p么t pr茅cise que les actions ont 茅t茅 acquises en tant que 谤茅尘耻苍茅谤补迟颈辞苍 de l鈥櫭﹎etteur le 17/11/2023 et que le paiement a 茅t茅 enregistr茅 脿 cette date. Le formulaire indique un total d鈥檃ctions en circulation de 168 712 220. Plusieurs champs standard d鈥檌dentification du d茅posant et de l鈥櫭﹎etteur sont laiss茅s blancs et aucun nom n鈥檈st fourni pour la personne au nom de laquelle la vente aura lieu.
Acadia Pharmaceuticals (ACAD) hat ein Formular 144 eingereicht, um einen geplanten Verkauf von Wertpapieren anzuzeigen. Die Mitteilung nennt 22.000 Stammaktien, die voraussichtlich 眉ber Piper Sandler & Co. um den 18.08.2025 verkauft werden sollen, mit einem Gesamtmarktwert von $557.260,00. In der Einreichung hei脽t es, die Aktien seien als 痴别谤驳眉迟耻苍驳 vom Emittenten am 17.11.2023 erworben worden und die Zahlung sei an diesem Datum verbucht worden. Das Formular gibt die Gesamtanzahl ausstehender Aktien mit 168.712.220 an. Mehrere standardm盲脽ige Felder zur Identifikation des Meldenden und des Emittenten sind im Formular leer, und es wird kein Name der Person angegeben, auf deren Konto der Verkauf erfolgen soll.
- None.
- None.
Insights
TL;DR: Routine Form 144 notice for a director/insider sale with standard brokerage execution; no material new disclosures.
The filing documents a proposed sale of 22,000 common shares via Piper Sandler with an indicated market value of $557,260 and an approximate sale date of 08/18/2025. The shares were acquired as compensation on 11/17/2023. The notice lacks identifying filer and issuer contact details and does not name the selling person, which is an omission for transparency though not necessarily a compliance fatality if the full form elsewhere contains those details. No recent sales in the past three months are reported.
TL;DR: Administrative disclosure of a planned insider sale; impact appears neutral absent other context.
The document indicates an insider-originated sale notification rather than a company action. Key facts鈥攓uantity (22,000 shares), acquisition as compensation (11/17/2023), broker (Piper Sandler), and planned sale date (08/18/2025)鈥攁re clearly recorded. The absence of the seller's name in the visible excerpt reduces standalone clarity; investors relying on issuer identity should consult the full filing record for complete names and signatures.
Acadia Pharmaceuticals (ACAD) ha presentato un Modulo 144 per notificare una proposta di vendita di titoli. L鈥檃vviso indica la vendita di 22.000 azioni ordinarie tramite Piper Sandler & Co. intorno al 18/08/2025, con un valore di mercato complessivo di $557.260,00. La comunicazione riporta che le azioni sono state acquisite come retribuzione dall鈥檈mittente il 17/11/2023 e che il pagamento 猫 stato registrato in quella data. Il documento indica un totale di azioni in circolazione pari a 168.712.220. Diversi campi standard relativi all鈥檌dentificazione del dichiarante e dell鈥檈mittente nel modulo risultano vuoti e non 猫 fornito il nome della persona per conto della quale avverr脿 la vendita.
Acadia Pharmaceuticals (ACAD) present贸 un Formulario 144 para notificar una propuesta de venta de valores. El aviso identifica 22.000 acciones ordinarias que se vender谩n a trav茅s de Piper Sandler & Co. alrededor del 18/08/2025, con un valor de mercado agregado de $557.260,00. La presentaci贸n indica que las acciones se adquirieron como 谤别迟谤颈产耻肠颈贸苍 por parte del emisor el 17/11/2023 y que el pago se registr贸 en esa fecha. El formulario se帽ala un total de acciones en circulaci贸n de 168.712.220. Varios campos est谩ndar de identificaci贸n del declarante y del emisor en el formulario est谩n en blanco y no se proporciona el nombre de la persona en cuya cuenta se realizar谩 la venta.
Acadia Pharmaceuticals(ACAD)臧赌 歃濌秾 毵り皝 鞓堨爼 靷嫟鞚� 韱奠頃橁赴 鞙勴暣 Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 瓿奠鞐愲姅 22,000欤� 氤错喌欤�臧赌 Piper Sandler & Co.毳� 韱淀暣 2025/08/18瓴� 毵り皝霅� 鞓堨爼鞚措┌, 齑� 鞁滉岸年岸� $557,260.00搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滌棎電� 頃措嫻 欤检嫕鞚� 氤挫垬(氤挫儊)搿� 氚滍枆靷攵�韯� 2023/11/17鞐� 旆摑霅橃棃瓿� 攴� 雮犾鞐� 歆�旮夓澊 旮半霅橃棃雼り碃 鞝來榾 鞛堨姷雼堧嫟. 靹滊鞐愲姅 齑� 氚滍枆欤检嫕靾橁岸� 168,712,220欤茧 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞏戩嫕鞚� 鞐煬 響滌 鞁犼碃鞚� 氚� 氚滍枆鞚� 鞁濍硠 頃鞚� 牍勳柎 鞛堦碃, 毵り皝鞚� 鞚措（鞏挫 瓿勳鞚� 鞁れ牅 氇呾弓鞚� 鞝滉车霅橃 鞎婌晿鞀惦媹雼�.
Acadia Pharmaceuticals (ACAD) a d茅pos茅 un formulaire 144 pour notifier une vente propos茅e de titres. L鈥檃vis indique la vente de 22 000 actions ordinaires par l鈥檌nterm茅diaire de Piper Sandler & Co. autour du 18/08/2025, pour une valeur marchande totale de 557 260,00 $. Le d茅p么t pr茅cise que les actions ont 茅t茅 acquises en tant que 谤茅尘耻苍茅谤补迟颈辞苍 de l鈥櫭﹎etteur le 17/11/2023 et que le paiement a 茅t茅 enregistr茅 脿 cette date. Le formulaire indique un total d鈥檃ctions en circulation de 168 712 220. Plusieurs champs standard d鈥檌dentification du d茅posant et de l鈥櫭﹎etteur sont laiss茅s blancs et aucun nom n鈥檈st fourni pour la personne au nom de laquelle la vente aura lieu.
Acadia Pharmaceuticals (ACAD) hat ein Formular 144 eingereicht, um einen geplanten Verkauf von Wertpapieren anzuzeigen. Die Mitteilung nennt 22.000 Stammaktien, die voraussichtlich 眉ber Piper Sandler & Co. um den 18.08.2025 verkauft werden sollen, mit einem Gesamtmarktwert von $557.260,00. In der Einreichung hei脽t es, die Aktien seien als 痴别谤驳眉迟耻苍驳 vom Emittenten am 17.11.2023 erworben worden und die Zahlung sei an diesem Datum verbucht worden. Das Formular gibt die Gesamtanzahl ausstehender Aktien mit 168.712.220 an. Mehrere standardm盲脽ige Felder zur Identifikation des Meldenden und des Emittenten sind im Formular leer, und es wird kein Name der Person angegeben, auf deren Konto der Verkauf erfolgen soll.
FAQ
What securities does the ACAD Form 144 propose to sell?
When is the proposed sale date listed on the ACAD Form 144?
What is the aggregate market value of the shares to be sold in the ACAD filing?
How were the shares being sold acquired according to the Form 144?
Which broker is named to execute the sale in the ACAD Form 144?
Does the filing list recent sales by the seller in the past three months?
Is the identity of the person on whose account the securities will be sold provided in this excerpt?
